Medtide Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides and based in Hangzhou, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange for the second time. This move comes after the company’s initial attempt in May of this year, with the unit price still undisclosed.
Medtide’s Extensive Pipeline and Focus on Polypeptides
As of June 30, 2024, Medtide has an impressive pipeline with 1046 ongoing CRO (Contract Research Organization) programs and 332 CDMO (Contract Development and Manufacturing Organization) programs. The company’s focus is on generic peptide active pharmaceutical ingredient (API) products that target diabetes, gastrointestinal diseases, and tumors. Medtide’s investigational generic peptide products include copies of tirzepatide, difelikefalin, triptorelin, and others, showcasing the company’s commitment to expanding access to critical polypeptide therapies.-Fineline Info & Tech
